CRN on omega-3s
This article was originally published in The Tan Sheet
A white paper on the "the importance of Omega-3 fatty acids for heart health" notes that following review by FDA and the American Heart Association, "when it comes to omega-3s and heart health, the evidence is strongest for EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid)," the Council for Responsible Nutrition states. The paper was released July 20 by CRN's Omega-3 Working Group. "It is important to educate various audiences on the benefits obtained from the different types of omega-3 fatty acids," according to Ian Newton, executive director of the working group. The paper "helps clarify some of the differences." FDA approved a qualified health claim for EPA and DHA in September (1"The Tan Sheet" Sept. 13, 2004, p. 12)...
You may also be interested in...
FDA's qualified health claim linking omega-3 fatty acids to coronary heart disease too narrowly interprets the beneficial relationship, dietary supplement industry stakeholders contend
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.